CDC-RFA-CD-23-0057: Increasing Public Awareness and Provider Education About Primary Immunodeficiency Disease
Closed
This grant is closed. A newer notice from the same program is forecast: Health Promotion and Disease Prevention Research Centers: 2027 Special Interest Project Supplements (SIPS) (RFA-DP-27-030). Status: Expected deadline March 23, 2027. It is in our archive of Centers for Disease Control - OD notices from 2023.
Centers for Disease Control - OD offered grants of up to $3.0 million (at least $1.0 million) to any type of organization. It expected to make one award worth $15.0 million in total. Applications closed on May 22, 2023.
From the official notice on Grants.gov, last changed April 7, 2023. Checked November 7, 2026.
- Award ceiling$3.0 million
- Award floor$1.0 million
- Total funding$15.0 million
- Expected awards1
- Cost sharingNot required
- Funding typeGrant
Key dates
| Posted | April 7, 2023 |
|---|---|
| Deadline | May 22, 2023 |
| Archived by Grants.gov | June 22, 2023 |
Who can apply
This opportunity was open to any type of organization.
All 13 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Is this a realistic fit?
- Past Centers for Research and Demonstration for Health Promotion and Disease Prevention awards averaged $2.0 million; this notice allows up to $3.0 million per award.
- No cost sharing or match is required.
What the grant funds
Primary Immunodeficiency Diseases (PID) are a group of primarily single-gene disorders of the immune system. Primary denotes the genetic nature of the defects, differentiating them from secondary or acquired immunodeficiencies caused by malnutrition, infection, chemotherapy, or other external agents. The defining characteristics of primary immunodeficiency diseases make them candidates for a public health intervention approach. Although the clinical manifestations and underlying genetic defects are diverse, primary immunodeficiency diseases share the common feature of increased susceptibility to infection and collectively result in substantial morbidity and shortened life spans. However prompt diagnosis and treatment can be lifesaving and may result in marked improvements in the quality and length of life. The heterogeneity of primary immunodeficiency diseases and the limited understanding of the relation between genotype and phenotype also hinder intervention efforts. Additional obstacles include the difficulty of diagnosis in the absence of a high index of suspicion and the lack of awareness of health care providers and the public which impedes the timely recognition of affected person by using a combination of clinical suspicion and diagnostic testing.
Who has won Centers for Research and Demonstration for Health Promotion and Disease Prevention grants before
From fiscal 2021 to 2025, Centers for Research and Demonstration for Health Promotion and Disease Prevention (93.135) awarded $131 million across 67 grant awards, an average of $2.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Emory University | Georgia | 2 | $9.2 million |
| University of Washington | Washington | 1 | $7.8 million |
| New York University | New York | 3 | $7.3 million |
| University of North Carolina at Chapel Hill | North Carolina | 2 | $7.1 million |
| Regents of the University of Michigan | Michigan | 3 | $6.6 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, RFA-DP-27-030, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-CD-23-0057 still open?
No. It closed on May 22, 2023. A newer notice is forecast: RFA-DP-27-030, expected deadline March 23, 2027.
Who can apply for Increasing Public Awareness and Provider Education About Primary Immunodeficiency Disease?
Centers for Disease Control - OD accepted applications from any type of organization.
What is the deadline for Increasing Public Awareness and Provider Education About Primary Immunodeficiency Disease?
Closed May 22, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $3.0 million each. About $15.0 million in total for one award.
Who has won Centers for Research and Demonstration for Health Promotion and Disease Prevention grants before?
The largest recipients over five fiscal years were Emory University, University of Washington, New York University. The program made 67 awards worth $131 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)